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The prognosis of patients with high-grade glioma remains
grim despite improvements in standard therapies includ-
ing surgery, radiation and chemotherapy. Immunotherapy
approaches targeting brain tumors offer promise over
conventional treatments by harnessing the potency and
specificity of the immune system. We have developed a
chimeric antigen receptor (CAR) T cell immunotherapy
for malignant glioma targeting IL-13 receptor a2
(IL13Ra2), a cell surface receptor over-expressed by a
high percentage of high-grade gliomas, but not expressed
at significant levels on normal brain tissue. Bioinformatic
studies demonstrated that expression of IL13Ra2 is asso-
ciated with increased glioma malignancy grade, mesenchy-
mal signature gene expression, and reduced patient
survival (top ~1% of single genes associated with
GBM survival). Previous pre-clinical efforts employing
1st-generation CAR T cell clones comprised of a mem-
brane-tethered IL-13 ligand and the intracellular CD3-zeta
endodomain (termed IL13-zetakine) demonstrated potent
MHC-independent IL13Ra2 anti-glioma activity against
both bulk glioma populations, and glioma stem-like tumor
propagating cells. Orthotopic glioma mouse models,
however, suggest that multiple infusions of IL13-zetakine+
T cells are required for anti-tumor efficacy since T cell
persistence is limited for these 1st-generation CAR
T clones. Importantly, completion of two FDA-authorized
Phase I clinical trials, evaluating both autologous and
allogeneic IL13-zetakine T cell clones in 9 patients,
demonstrates the feasibility of this approach, absence of
serious side-effects, and provide evidence for transient
anti-glioma tumor responses for patients with IL13Ra2pos
glioblastomas. We now aim to enhance therapeutic effi-
cacy of this approach by augmenting T cell effector func-
tion through the expression of CARs with co-stimulatory
signaling in T cell population capable of long-term
persistence. Indeed, we find that a single administration
of central memory T cells engineered to express a
2nd-generation IL13-41BB-zetakine CAR can eradicate
established glioma tumors in mice, thus outperforming
the 1st-generation IL13-zetakine+ T cells. These findings
support the potential for treating patients with high-grade
glioma with IL13Ra2-specific CAR-engineered T cells.
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